Technology

Constellation Pharmaceuticals

$34.88
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.23 (-0.66%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell CNST and other stocks, options, and ETFs commission-free!

About CNST

Constellation Pharmaceuticals, Inc. Common Stock, also called Constellation Pharmaceuticals, is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The company utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product candidates include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA. The listed name for CNST is Constellation Pharmaceuticals, Inc. Common Stock.

CEO
Jigar Raythatha
Employees
106
Headquarters
Cambridge, Massachusetts
Founded
2008
Market Cap
1.61B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
635.47K
High Today
$36.75
Low Today
$33.47
Open Price
$34.29
Volume
514.14K
52 Week High
$50.90
52 Week Low
$17.00

Collections

CNST Earnings

-$0.82
-$0.55
-$0.27
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 4, Pre-Market

You May Also Like

PMAR
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure